-
Molecular and Cellular Endocrinology Jan 2023Nephrogenic diabetes insipidus is defined as an inability to concentrate urine due to a complete or partial alteration of the renal tubular response to arginine... (Review)
Review
Nephrogenic diabetes insipidus is defined as an inability to concentrate urine due to a complete or partial alteration of the renal tubular response to arginine vasopressin hormone, resulting in excessive diluted urine excretion. Hereditary forms are caused by molecular defects in the genes encoding either of the two main renal effectors of the arginine vasopressin pathway: the AVPR2 gene, which encodes for the type 2 vasopressin receptor, or the AQP2 gene, which encodes for the water channel aquaporin-2. About 90% of cases of nephrogenic diabetes insipidus result from loss-of-function variants in the AVPR2 gene, which are inherited in a X-linked recessive manner. The remaining 10% of cases result from loss-of-function variants in the AQP2 gene, which can be inherited in either a recessive or a dominant manner. The main symptoms of the disease are polyuria, chronic dehydration and hypernatremia. These symptoms usually occur in the first year of life, although some patients present later. Diagnosis is based on abnormal response in urinary osmolality after water restriction and/or administration of exogenous vasopressin. Treatment involves ensuring adequate water intake on demand, possibly combined with thiazide diuretics, non-steroidal anti-inflammatory drugs, and a low-salt and protein diet. In this review, we provide an update on current understanding of the molecular basis of inherited nephrogenic insipidus diabetes.
Topics: Humans; Aquaporin 2; Arginine Vasopressin; Diabetes Insipidus, Nephrogenic; Mutation; Receptors, Vasopressin
PubMed: 36460218
DOI: 10.1016/j.mce.2022.111825 -
Frontiers in Endocrinology 2023The diluting and concentrating function of the kidney plays a crucial role in regulating the water homeostasis of the body. This function is regulated by the... (Review)
Review
The diluting and concentrating function of the kidney plays a crucial role in regulating the water homeostasis of the body. This function is regulated by the antidiuretic hormone, arginine vasopressin through the type 2 vasopressin receptor (V2R), allowing the body to adapt to periods of water load or water restriction. Loss-of-function mutations of the V2R cause X-linked nephrogenic diabetes insipidus (XNDI), which is characterized by polyuria, polydipsia, and hyposthenuria. Gain-of-function mutations of the V2R lead to nephrogenic syndrome of inappropriate antidiuresis disease (NSIAD), which results in hyponatremia. Various mechanisms may be responsible for the impaired receptor functions, and this review provides an overview of recent findings about the potential therapeutic interventions in the light of the current experimental data.
Topics: Receptors, Vasopressin; Vasopressins; Mutation; Water; Molecular Biology
PubMed: 37293495
DOI: 10.3389/fendo.2023.1173601 -
Expert Opinion on Therapeutic Patents Jun 2015The vasopressin V1a and V1b receptors are involved in many crucial physiological, reproductive, behavioral and social functions. Consequently, they are also involved in... (Review)
Review
INTRODUCTION
The vasopressin V1a and V1b receptors are involved in many crucial physiological, reproductive, behavioral and social functions. Consequently, they are also involved in several pathological conditions, thus the ligands capable of selective stimulation/inhibition of these receptors may present therapeutic benefit in a variety of diseases.
AREAS COVERED
In this review, the author focuses on the vasopressin V1a and V1b receptors, their biological functions and agonists and antagonists patented in the years 2012 - 2014. This paper is divided according to both the target receptor and the applicant and describes the compounds from the patents along with their biological activity.
EXPERT OPINION
In the recent years, pharmaceutical companies have discovered and patented new compounds which act through vasopressin V1a and/or V1b receptors, both peptide and non-peptide. Among the V1bR antagonists published in the last years, the oxindole derivatives appear to be the most promising drug candidates.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Drug Design; Humans; Indoles; Ligands; Oxindoles; Patents as Topic; Peptides; Receptors, Vasopressin
PubMed: 25776143
DOI: 10.1517/13543776.2015.1026257 -
Frontiers in Endocrinology 2023The diabetic kidney disease (DKD) is the major cause of the chronic kidney disease (CKD). Enhanced plasma vasopressin (VP) levels have been associated with the... (Review)
Review
The diabetic kidney disease (DKD) is the major cause of the chronic kidney disease (CKD). Enhanced plasma vasopressin (VP) levels have been associated with the pathophysiology of DKD and CKD. Stimulation of VP release in DKD is caused by glucose-dependent reset of the osmostat leading to secondary pathophysiologic effects mediated by distinct VP receptor types. VP is a stress hormone exhibiting the antidiuretic action in the kidney along with broad adaptive effects in other organs. Excessive activation of the vasopressin type 2 (V2) receptor in the kidney leads to glomerular hyperfiltration and nephron loss, whereas stimulation of vasopressin V1a or V1b receptors in the liver, pancreas, and adrenal glands promotes catabolic metabolism for energy mobilization, enhancing glucose production and aggravating DKD. Increasing availability of selective VP receptor antagonists opens new therapeutic windows separating the renal and extra-renal VP effects for the concrete applications. Improved understanding of these paradigms is mandatory for further drug design and translational implementation. The present concise review focuses on metabolic effects of VP affecting DKD pathophysiology.
Topics: Humans; Diabetic Nephropathies; Vasopressins; Receptors, Vasopressin; Renal Insufficiency, Chronic; Glucose; Diabetes Mellitus
PubMed: 37790608
DOI: 10.3389/fendo.2023.1176199 -
British Journal of Pharmacology Apr 2022Oxytocin (OT) and vasopressin (AVP) are endogenous ligands for OT and AVP receptors in the brain and in the peripheral system. Several studies demonstrate that OT and... (Review)
Review
Oxytocin (OT) and vasopressin (AVP) are endogenous ligands for OT and AVP receptors in the brain and in the peripheral system. Several studies demonstrate that OT and AVP have opposite roles in modulating stress, anxiety and social behaviours. Interestingly, both peptides and their receptors exhibit high sequence homology which could account for the biased signalling interaction of the peptides with OT and AVP receptors. However, how and under which conditions this crosstalk occurs in vivo remains unclear. In this review we shed light on the complexity of the roles of OT and AVP, by focusing on their signalling and behavioural differences and exploring the crosstalk between the receptor systems. Moreover, we discuss the potential of OT and AVP receptors as therapeutic targets to treat human disorders, such as autism, schizophrenia and drug abuse. LINKED ARTICLES: This article is part of a themed issue on Building Bridges in Neuropharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.8/issuetoc.
Topics: Brain; Humans; Ligands; Oxytocin; Receptors, Oxytocin; Receptors, Vasopressin; Social Behavior; Vasopressins
PubMed: 33817785
DOI: 10.1111/bph.15481 -
Advances in Experimental Medicine and... 2023Disruption of water and electrolyte balance is frequently encountered in clinical medicine. Regulating water metabolism is critically important. Diabetes insipidus (DI)...
Disruption of water and electrolyte balance is frequently encountered in clinical medicine. Regulating water metabolism is critically important. Diabetes insipidus (DI) presented with excessive water loss from the kidney is a major disorder of water metabolism. To understanding the molecular and cellular mechanisms and pathophysiology of DI and rationales of clinical management of DI is important for both research and clinical practice. This chapter will first review various forms of DI focusing on central diabetes insipidus (CDI) and nephrogenic diabetes insipidus (NDI). This is followed by a discussion of regulatory mechanisms underlying CDI and NDI, with a focus on the regulatory axis of vasopressin, vasopressin receptor 2 (V2R) and the water channel molecule, aquaporin 2 (AQP2). The clinical manifestation, diagnosis, and management of various forms of DI will also be discussed with highlights of some of the latest therapeutic strategies that are developed from in vitro experiments and animal studies.
Topics: Animals; Aquaporin 2; Diabetes Insipidus, Nephrogenic; Diabetes Insipidus; Aquaporins; Kidney; Water; Mutation; Receptors, Vasopressin; Diabetes Mellitus
PubMed: 36717500
DOI: 10.1007/978-981-19-7415-1_18 -
Expert Opinion on Therapeutic Patents 2023Arginine-vasopressin hormone (AVP) is a key regulator in many essential physiological processes. The effect of AVP is mediated through three receptors within the body,... (Review)
Review
INTRODUCTION
Arginine-vasopressin hormone (AVP) is a key regulator in many essential physiological processes. The effect of AVP is mediated through three receptors within the body, these are the G protein-coupled vasopressin receptors, namely V1a, V1b (also called V3), and V2. Numerous studies investigated the role of these receptors in certain pathological conditions; therefore, stimulation or inhibition of these receptors may be a treatment option in these diseases.
AREAS COVERED
In this manuscript, the authors summarize recent patent activity (2018-2022) associated with vasopressin receptor antagonists (selective V1a or V2, and dual-acting V1a/V2), focusing mostly on chemical structures, their modifications, and potential clinical applications. Patent search was carried out using SciFinder, Espacenet, Patentscope, Cortellis Competitive Intelligence, and Derwent Innovation databases.
EXPERT OPINION
In recent years, vasopressin receptor antagonists have been in the spotlight of drug discovery, especially V1a selective molecules. Publishing balovaptan as a possible treatment for autism spectrum disorder (ASD), greatly increased the interest in CNS-acting vasopressin antagonists. In addition, peripherally active selective V2 and dual-acting V1a/V2 antagonists have also been developed. Although clinical trials were unsuccessful in many cases, there is still potential in the research of vasopressin receptor antagonists as shown by several currently ongoing clinical trials.
Topics: Antidiuretic Hormone Receptor Antagonists; Patents as Topic; Drug Development; Research; Clinical Trials as Topic; Humans; Receptors, Vasopressin
PubMed: 37226495
DOI: 10.1080/13543776.2023.2218546 -
Current Neuropharmacology Nov 2022The arginine vasopressin (AVP), a neurohypophysial hormone, is synthesized within specific sites of the central nervous system and axonally transported to multiple... (Review)
Review
The arginine vasopressin (AVP), a neurohypophysial hormone, is synthesized within specific sites of the central nervous system and axonally transported to multiple areas, acting as a neurotransmitter/ neuromodulator. In this context, AVP acts primarily through vasopressin receptors A and B and is involved in regulating complex social and cognition behaviors and basic autonomic function. Many earlier studies have shown that AVP as a neuromodulator affects synaptic plasticity. This review updates our current understanding of the underlying molecular mechanisms by which AVP affects synaptic plasticity. Moreover, we discuss AVP modulatory effects on event-related potentials and blood oxygen level-dependent responses in specific brain structures, and AVP effects on the network level oscillatory activity. We aimed at providing an overview of the AVP effects on the brain from the synaptic to the network level.
Topics: Humans; Arginine Vasopressin; Receptors, Vasopressin; Brain; Neuronal Plasticity; Neurotransmitter Agents
PubMed: 35193483
DOI: 10.2174/1570159X20666220222143532 -
Vitamins and Hormones 2020We previously characterized the arginine vasotocin receptor sequences in the jawless vertebrate sea lamprey. These gene and protein sequences provide clues to the... (Review)
Review
We previously characterized the arginine vasotocin receptor sequences in the jawless vertebrate sea lamprey. These gene and protein sequences provide clues to the origins of the various arginine vasopressin and oxytocin receptor family members in jawed vertebrates. However, orthological relationships between the jawless and jawed receptors is unclear. The current work is a closer examination and comparison between these G protein-coupled receptor sequences of the lamprey, the early jawed vertebrate elephant shark, and the boned fish and tetrapods. Our objective was to gain more insight into the differentiation of key signaling domains, which may then aid in discerning the pattern and timing of whole genome duplication early in the vertebrate lineage. The lamprey receptors remain less differentiated than shark receptors, due in part to the single vasotocin ligand in the lamprey and the selection pressure of a second ligand, oxytocin, in the shark. However, variation in G proteins utilized among the V1A, V1B and oxytocin receptor types has also contributed to differentiation, as well as leading to a change in second-messenger signaling pathway in the V2-type receptors. Conservation of gene regulatory elements may provide additional evidence of receptor gene orthology. These molecular evolution studies can ultimately be informative in applications such as drug discovery and environmental toxicology to determine cross-species sensitivity to chemicals.
Topics: Animals; Fishes; Receptors, Oxytocin; Receptors, Vasopressin; Vasotocin; Vertebrates
PubMed: 32138945
DOI: 10.1016/bs.vh.2019.08.018 -
The International Journal of... Jul 2021Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP)... (Review)
Review
Accumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V1B receptor) play a pivotal role in HPA axis abnormalities observed in depression. Based on this hypothesis, several non-peptide V1B receptor antagonists have been synthesized, and the efficacies of some V1B receptor antagonists have been investigated in both animals and humans. V1B receptor antagonists exert antidepressant-like effects in several animal models at doses that attenuate the hyperactivity of the HPA axis, and some of their detailed mechanisms have been delineated. These results obtained in animal models were, at least partly, reproduced in clinical trials. At least 2 V1B receptor antagonists (TS-121 and ABT-436) showed tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1B receptor. Importantly, TS-121 showed a clearer efficacy for patients with higher basal cortisol levels than for those with lower basal cortisol levels, which was consistent with the hypothesis that V1B receptor antagonists may be more effective for patients with HPA axis hyperactivity. Therefore, V1B receptor antagonists are promising approaches for the treatment of depression involving HPA axis impairment such as depression.
Topics: Animals; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Depressive Disorder, Major; Humans; Hypothalamo-Hypophyseal System; Receptors, Vasopressin
PubMed: 33733667
DOI: 10.1093/ijnp/pyab013